These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30930207)

  • 21. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma.
    Labbate CV; Hensley PJ; Miest TS; Qiao W; Adibi M; Shah AY; Chery L; Papadopoulos J; Siefker-Radtke AO; Gao J; Guo CC; Czerniak BA; Navai N; Kamat AM; Dinney CP; Campbell MT; Matin SF
    Urol Oncol; 2022 Oct; 40(10):454.e17-454.e23. PubMed ID: 35961847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration.
    Necchi A; Lo Vullo S; Mariani L; Moschini M; Hendricksen K; Rink M; Sosnowski R; Dobruch J; Raman JD; Wood CG; Margulis V; Roupret M; Briganti A; Montorsi F; Xylinas E; Shariat SF;
    BJU Int; 2018 Feb; 121(2):252-259. PubMed ID: 28940605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma.
    Martini A; Falagario UG; Waingankar N; Daza J; Treacy PJ; Necchi A; Galsky MD; Sfakianos JP
    Urol Oncol; 2020 Aug; 38(8):684.e9-684.e15. PubMed ID: 32284255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review.
    Cutress ML; Stewart GD; Zakikhani P; Phipps S; Thomas BG; Tolley DA
    BJU Int; 2012 Sep; 110(5):614-28. PubMed ID: 22471401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
    Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J
    Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of neoadjuvant chemotherapy on survival prognosis and pathological downstaging in patients presenting with high-risk upper tract urothelial carcinoma: A protocol for systematic review and meta analysis.
    Li K; Xie W; Gao L; Huang G; Zhou J; Mei B; Chen J
    Medicine (Baltimore); 2020 May; 99(18):e20184. PubMed ID: 32358407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy.
    Kaag MG; O'Malley RL; O'Malley P; Godoy G; Chen M; Smaldone MC; Hrebinko RL; Raman JD; Bochner B; Dalbagni G; Stifelman MD; Taneja SS; Huang WC
    Eur Urol; 2010 Oct; 58(4):581-7. PubMed ID: 20619530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma.
    Kim JK; Moon KC; Jeong CW; Kwak C; Kim HH; Ku JH
    Urol Oncol; 2017 Jul; 35(7):458.e9-458.e15. PubMed ID: 28347659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
    Hamaya T; Hatakeyama S; Tanaka T; Kubota Y; Togashi K; Hosogoe S; Fujita N; Kusaka A; Tokui N; Okamoto T; Yamamoto H; Yoneyama T; Yoneyama T; Hashimoto Y; Ohyama C
    BJU Int; 2021 Oct; 128(4):468-476. PubMed ID: 33484231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant Chemotherapy Benefits Survival in High-Grade Upper Tract Urothelial Carcinoma: A Propensity Score-Based Analysis.
    Chen L; Ou Z; Wang R; Zhang M; He W; Zhang J; Zu X; Yi L; Xu R; Jiang S; Qi L; Wang L
    Ann Surg Oncol; 2020 Apr; 27(4):1297-1303. PubMed ID: 31853757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urothelial cancer: Optimizing and integrating cisplatin-based chemotherapy across the disease spectrum.
    Raman JD
    Nat Rev Urol; 2018 Mar; 15(3):139-140. PubMed ID: 29335525
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of the Clinical Utility of Renin-Angiotensin System Inhibitors in Patients Undergoing Radical Surgery for Urothelial Carcinoma of the Upper Urinary Tract.
    Yoshida T; Matsuzaki T; Murota T; Kawa G; Matsuda T; Kinoshita H
    Clin Genitourin Cancer; 2017 Dec; 15(6):e943-e954. PubMed ID: 28552573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study.
    Grossmann NC; Pradere B; D'Andrea D; Schuettfort VM; Mori K; Rajwa P; Quhal F; Laukhtina E; Katayama S; Fankhauser CD; Xylinas E; Margulis V; Moschini M; Abufaraj M; Bandini M; Lonati C; Nyirady P; Karakiewicz PI; Fajkovic H; Shariat SF
    Clin Genitourin Cancer; 2022 Jun; 20(3):227-236. PubMed ID: 35125303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma.
    Pradere B; D'Andrea D; Schuettfort VM; Foerster B; Quhal F; Mori K; Abufaraj M; Margulis V; Deuker M; Briganti A; Muilwijk T; Hendricksen K; Lotan Y; Karakiewic P; F Shariat S;
    World J Urol; 2021 Jul; 39(7):2567-2577. PubMed ID: 33067726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma.
    Ghandour RA; Freifeld Y; Cheaib J; Singla N; Meng X; Kenigsberg A; Bagrodia A; Woldu S; Hoffman-Censits J; Enikeev D; Rapoport L; Petros FG; Raman JD; Pierorazio PM; Matin SF; Margulis V
    Urol Oncol; 2021 Nov; 39(11):788.e15-788.e21. PubMed ID: 34330655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience.
    Cutress ML; Stewart GD; Wells-Cole S; Phipps S; Thomas BG; Tolley DA
    BJU Int; 2012 Dec; 110(11):1608-17. PubMed ID: 22564677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma.
    Emamekhoo H; Dhillon P; Gopalakrishnan D; Elson P; Stephenson A; Magi-Galluzzi C; McKenney J; Harper H; Haber GP; Kaouk J; Lee B; Fergany A; Berglund R; Gong M; Stein R; Krishnamurthi V; Gilligan T; Ornstein M; Rini B; Garcia J; Grivas P
    Clin Genitourin Cancer; 2018 Aug; 16(4):e751-e760. PubMed ID: 29551583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Lymphadenectomy During Radical Nephroureterectomy in Locally Advanced Upper Tract Urothelial Carcinoma.
    Ikeda M; Matsumoto K; Sakaguchi K; Ishii D; Tabata KI; Kurosawa K; Urakami S; Okaneya T; Iwamura M
    Clin Genitourin Cancer; 2017 Oct; 15(5):556-562. PubMed ID: 28501481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy.
    Rodrigues Pessoa R; Morrison JC; Konety B; Gershman B; Maroni P; Kukreja JB; Cost N; Flaig T; Kessler E; Sharma P; Kim SP
    Urol Oncol; 2021 Dec; 39(12):832.e9-832.e15. PubMed ID: 33820697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caveolin-1 Expression in Upper Tract Urothelial Carcinoma.
    D'Andrea D; Moschini M; Foerster B; Abufaraj M; Margulis V; Karam J; Lotan Y; Raman J; Mathieu R; Rouprêt M; Karakiewicz PI; Briganti A; Haitel A; Shariat SF
    Eur Urol Focus; 2019 Jan; 5(1):97-103. PubMed ID: 28753840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.